WO2001000186A3 - New use of 1,2,4-triazolo'1,5-a! pyrimidines - Google Patents

New use of 1,2,4-triazolo'1,5-a! pyrimidines Download PDF

Info

Publication number
WO2001000186A3
WO2001000186A3 PCT/EP2000/005543 EP0005543W WO0100186A3 WO 2001000186 A3 WO2001000186 A3 WO 2001000186A3 EP 0005543 W EP0005543 W EP 0005543W WO 0100186 A3 WO0100186 A3 WO 0100186A3
Authority
WO
WIPO (PCT)
Prior art keywords
triazolo
pyrimidines
new use
eating
enatiomers
Prior art date
Application number
PCT/EP2000/005543
Other languages
French (fr)
Other versions
WO2001000186A2 (en
Inventor
Ian Charles Kilpatrick
Original Assignee
Knoll Gmbh
Ian Charles Kilpatrick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll Gmbh, Ian Charles Kilpatrick filed Critical Knoll Gmbh
Priority to JP2001505896A priority Critical patent/JP2003503343A/en
Priority to CA002376886A priority patent/CA2376886A1/en
Priority to MXPA01013421A priority patent/MXPA01013421A/en
Priority to AU61502/00A priority patent/AU6150200A/en
Priority to EP00947848A priority patent/EP1218008A2/en
Publication of WO2001000186A2 publication Critical patent/WO2001000186A2/en
Publication of WO2001000186A3 publication Critical patent/WO2001000186A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A method of treating obesity and related conditions, selected from eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, comprising the administration of therapeutically effective amount of a compound of formula I including pharmaceutically acceptable salts, solvates, racemates, enatiomers, diastereoisomers and mixtures thereof. Most preferred compounds are 7-[1-(4-halophenoxy) ethyl] 1,2,4,-triazolo [1,5a] pyrimidines
PCT/EP2000/005543 1999-06-24 2000-06-16 New use of 1,2,4-triazolo'1,5-a! pyrimidines WO2001000186A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001505896A JP2003503343A (en) 1999-06-24 2000-06-16 Therapeutic agent
CA002376886A CA2376886A1 (en) 1999-06-24 2000-06-16 Therapeutic agents
MXPA01013421A MXPA01013421A (en) 1999-06-24 2000-06-16 Therapeutic agents.
AU61502/00A AU6150200A (en) 1999-06-24 2000-06-16 Therapeutic agents
EP00947848A EP1218008A2 (en) 1999-06-24 2000-06-16 New use of 1,2,4-triazolo[1,5-a]pyrimidines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9914743.1 1999-06-24
GBGB9914743.1A GB9914743D0 (en) 1999-06-24 1999-06-24 Therapeutic agents

Publications (2)

Publication Number Publication Date
WO2001000186A2 WO2001000186A2 (en) 2001-01-04
WO2001000186A3 true WO2001000186A3 (en) 2002-05-10

Family

ID=10855954

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005543 WO2001000186A2 (en) 1999-06-24 2000-06-16 New use of 1,2,4-triazolo'1,5-a! pyrimidines

Country Status (7)

Country Link
EP (1) EP1218008A2 (en)
JP (1) JP2003503343A (en)
AU (1) AU6150200A (en)
CA (1) CA2376886A1 (en)
GB (1) GB9914743D0 (en)
MX (1) MXPA01013421A (en)
WO (1) WO2001000186A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815875B2 (en) 2008-11-12 2014-08-26 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
US8759357B2 (en) 2009-10-08 2014-06-24 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (FABP)
KR101775682B1 (en) 2015-11-30 2017-09-06 주식회사 대웅 Methods for Preparing Botulinum Toxin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010521A1 (en) * 1993-10-13 1995-04-20 Knoll Ag Therapeutic agents
WO2000056292A2 (en) * 1999-03-18 2000-09-28 Knoll Gmbh Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine
WO2000056336A2 (en) * 1999-03-18 2000-09-28 Knoll Gmbh Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
WO2000056733A1 (en) * 1999-03-18 2000-09-28 Knoll Gmbh Triazolopyrimidinol compounds and salts thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010521A1 (en) * 1993-10-13 1995-04-20 Knoll Ag Therapeutic agents
WO2000056292A2 (en) * 1999-03-18 2000-09-28 Knoll Gmbh Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine
WO2000056336A2 (en) * 1999-03-18 2000-09-28 Knoll Gmbh Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin
WO2000056733A1 (en) * 1999-03-18 2000-09-28 Knoll Gmbh Triazolopyrimidinol compounds and salts thereof

Also Published As

Publication number Publication date
GB9914743D0 (en) 1999-08-25
AU6150200A (en) 2001-01-31
MXPA01013421A (en) 2002-07-30
EP1218008A2 (en) 2002-07-03
JP2003503343A (en) 2003-01-28
CA2376886A1 (en) 2001-01-04
WO2001000186A2 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
CA2287558A1 (en) Heterocyclic derivatives and their use as antithrombotic agents
CA2258949A1 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
AU2534295A (en) Gastrin and cck antagonists
CA2293621A1 (en) 4-aminopyrrole(3,2-d) pyrimidines as neuropeptide y receptor antagonists
CA2367666A1 (en) Method of treating eating disorders
CA2102179A1 (en) Quinuclidine derivatives
CA2382435A1 (en) Novel herbicidally active phenyl-substituted heterocycles
CA2146852A1 (en) New substituted pyrazole derivatives, processes for their preparation and their use as herbicides
UY25230A1 (en) DERIVATIVES OF D-PROLINE
CA2379640A1 (en) Certain alkylene diamine-substituted heterocycles
CA2297732A1 (en) Heterocyclic vinylethers against neurological disorders
CA2296665A1 (en) Triazolo[4,5-d]pyrimidine derivatives as anti-thromobotic agents
DE69329727D1 (en) NEW IMIDAZOLE DERIVATIVES, THEIR PRODUCTION AND THERAPEUTIC USE
CA2266050A1 (en) Piperazine derivatives
WO2002006286A3 (en) IMIDAZO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CA2086434A1 (en) Quinuclidine derivatives
CA2201477A1 (en) New pyrimidone derivatives with antifungal activity
WO2001066543A3 (en) 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
CA2260145A1 (en) Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
EP0630898A4 (en) Thrombocytopenia remedy.
EP0751126A4 (en) Benzene-fused heterocyclic derivative and use of the same
CA2176935A1 (en) Indole-derived azylpiperazines as ligands for 5ht1-like receptors 5ht1b and 5ht1d
WO2000027850A3 (en) Crf receptor antagonists and methods relating thereto
WO2001028974A3 (en) Intermediates for making a benzofuran or benzothiophene derivative nitrated in position 5 and uses thereof
WO2001000186A3 (en) New use of 1,2,4-triazolo'1,5-a! pyrimidines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2376886

Country of ref document: CA

Ref country code: CA

Ref document number: 2376886

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/013421

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 505896

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000947848

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10019111

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000947848

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000947848

Country of ref document: EP